Swiss National Bank
TSHA icon

Swiss National Bank’s Taysha Gene Therapies TSHA Stock Holding History

Swiss National Bank’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.51M Buy
369,000
+100,200
+37% +$593K ﹤0.01% 1809
2026
Q1 		$1.2M Hold
268,800
– – ﹤0.01% 2084
2025
Q4 		$1.48M Buy
+268,800
New +$1.31M ﹤0.01% 2002
2022
Q2 		– Sell
-41,000
Closed -$267K – 2792
2022
Q1 		$267K Buy
41,000
+3,500
+9% +$26.2K ﹤0.01% 2665
2021
Q4 		$437K Hold
37,500
– – ﹤0.01% 2685
2021
Q3 		$698K Hold
37,500
– – ﹤0.01% 2521
2021
Q2 		$795K Buy
+37,500
New +$864K ﹤0.01% 2548

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Swiss National Bank's TSHA Position: Q2 2026 in Review

Swiss National Bank increased its Taysha Gene Therapies (TSHA) stake by 37% in Q2 2026, buying an estimated $593K and bringing the position to 369,000 shares worth $2.51M. The position accounts for ﹤0.01% of the portfolio, ranked #1809.

Swiss National Bank first reported a position in TSHA in Q2 2021 and has held it in 7 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Swiss National Bank held 369,000 shares of Taysha Gene Therapies worth $2.51M as of Q2 2026.
  • Swiss National Bank bought 100,200 Taysha Gene Therapies shares in Q2 2026, an estimated $593K.
  • Taysha Gene Therapies made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1809 holding.
  • Swiss National Bank first reported a position in Taysha Gene Therapies in Q2 2021 and has held it in 7 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.